Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,015

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Pemphigoid diseases

Schmidt, Enno, Zillikens, Detlef·2013·The Lancet
DOI 10.1016/s0140-6736(12)61140-4
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(12)61140-4

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Research works printed but not linked: 88

  1. Ghohestani, 2000, The α5 chain of type IV collagen is the target of IgG autoantibodies in a novel autoimmune disease with subepidermal blisters and renal insufficiency, J Biol Chem, 275, 16002, 10.1074/jbc.275.21.16002 · doi:10.1074/jbc.275.21.16002
  2. Lever, 1953, Pemphigus, Medicine (Baltimore), 32, 1, 10.1097/00005792-195302000-00001 · doi:10.1097/00005792-195302000-00001
  3. Marazza, 2009, Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study, Br J Dermatol, 161, 861, 10.1111/j.1365-2133.2009.09300.x · doi:10.1111/j.1365-2133.2009.09300.x
  4. Gudi, 2005, Annual incidence and mortality of bullous pemphigoid in the Grampian region of north-east Scotland, Br J Dermatol, 153, 424, 10.1111/j.1365-2133.2005.06662.x · doi:10.1111/j.1365-2133.2005.06662.x
  5. Joly, 2012, Incidence and mortality of bullous pemphigoid in France, J Invest Dermatol, 132, 1998, 10.1038/jid.2012.35 · doi:10.1038/jid.2012.35
  6. Jung, 1999, Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence, J Am Acad Dermatol, 41, 266, 10.1016/S0190-9622(99)70061-7 · doi:10.1016/s0190-9622(99)70061-7
  7. Waisbourd-Zinman, 2008, Bullous pemphigoid in infancy: Clinical and epidemiologic characteristics, J Am Acad Dermatol, 58, 41, 10.1016/j.jaad.2007.08.010 · doi:10.1016/j.jaad.2007.08.010
  8. Cortes, 2011, Mortality of bullous pemphigoid in Switzerland: a prospective study, Br J Dermatol, 165, 368, 10.1111/j.1365-2133.2011.10413.x · doi:10.1111/j.1365-2133.2011.10413.x
  9. Bastuji-Garin, 2011, Risk factors for bullous pemphigoid in the elderly: a prospective case-control study, J Invest Dermatol, 131, 637, 10.1038/jid.2010.301 · doi:10.1038/jid.2010.301
  10. Taylor, 1993, Bullous pemphigoid and autoimmunity, J Am Acad Dermatol, 29, 181, 10.1016/0190-9622(93)70164-O · doi:10.1016/0190-9622(93)70164-o
  11. Lindelof, 1990, Pemphigoid and cancer, Arch Dermatol, 126, 66, 10.1001/archderm.1990.01670250072011 · doi:10.1001/archderm.1990.01670250072011
  12. Ogawa, 1995, The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan, J Dermatol Sci, 9, 136, 10.1016/0923-1811(94)00371-K · doi:10.1016/0923-1811(94)00371-k
  13. Venning, 1995, Induced bullous pemphigoid, Br J Dermatol, 132, 831, 10.1111/j.1365-2133.1995.tb00739.x · doi:10.1111/j.1365-2133.1995.tb00739.x
  14. Walmsley, 2011, Bullous pemphigoid triggered by swine flu vaccination: case report and review of vaccine triggered pemphigoid, J Dermatol Case Rep, 5, 74, 10.3315/jdcr.2011.1081 · doi:10.3315/jdcr.2011.1081
  15. Bastuji-Garin, 1996, Drugs associated with bullous pemphigoid—a case-control study, Arch Dermatol, 132, 272, 10.1001/archderm.1996.03890270044006 · doi:10.1001/archderm.1996.03890270044006 · Paper page
  16. Schmidt, 2011, Clinical features and practical diagnosis of bullous pemphigoid, Dermatol Clin, 29, 427, 10.1016/j.det.2011.03.010 · doi:10.1016/j.det.2011.03.010
  17. Murrell, 2011, Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts, J Am Acad Dermatol, 66, 479, 10.1016/j.jaad.2011.06.032 · doi:10.1016/j.jaad.2011.06.032
  18. Perriard, 1999, IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180, J Invest Dermatol, 112, 141, 10.1046/j.1523-1747.1999.00497.x · doi:10.1046/j.1523-1747.1999.00497.x
  19. Hofmann, 2002, Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain, J Invest Dermatol, 119, 1065, 10.1046/j.1523-1747.2002.19529.x · doi:10.1046/j.1523-1747.2002.19529.x
  20. Di Zenzo, 2004, Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients, J Invest Dermatol, 122, 103, 10.1046/j.0022-202X.2003.22126.x · doi:10.1046/j.0022-202x.2003.22126.x
  21. Iwata, 2008, Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid, Arch Dermatol, 144, 41, 10.1001/archdermatol.2007.9 · doi:10.1001/archdermatol.2007.9
  22. Skaria, 2000, IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomains of the COOH-terminus of BP230, J Invest Dermatol, 114, 998, 10.1046/j.1523-1747.2000.00893.x · doi:10.1046/j.1523-1747.2000.00893.x
  23. Delaporte, 1996, IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid, J Immunol, 157, 3642, 10.4049/jimmunol.157.8.3642 · doi:10.4049/jimmunol.157.8.3642
  24. Schmidt, 2000, Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid, Arch Dermatol, 136, 174, 10.1001/archderm.136.2.174 · doi:10.1001/archderm.136.2.174
  25. Iwata, 2009, IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment, J Invest Dermatol, 129, 919, 10.1038/jid.2008.305 · doi:10.1038/jid.2008.305
  26. Schmidt, 2000, Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes, J Invest Dermatol, 115, 842, 10.1046/j.1523-1747.2000.00141.x · doi:10.1046/j.1523-1747.2000.00141.x
  27. Gammon, 1982, An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement, J Invest Dermatol, 78, 285, 10.1111/1523-1747.ep12507222 · doi:10.1111/1523-1747.ep12507222
  28. Bieber, 2009, Animal models for autoimmune bullous dermatoses, Exp Dermatol, 19, 2, 10.1111/j.1600-0625.2009.00948.x · doi:10.1111/j.1600-0625.2009.00948.x
  29. Hirose, 2011, Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice, J Immunol, 187, 1176, 10.4049/jimmunol.1100596 · doi:10.4049/jimmunol.1100596
  30. Hall, 1993, Rabbits immunized with a peptide encoded for by the 230-kD bullous pemphigoid antigen cDNA develop an enhanced inflammatory response to UVB irradiation: a potential animal model for bullous pemphigoid, J Invest Dermatol, 101, 9, 10.1111/1523-1747.ep12358276 · doi:10.1111/1523-1747.ep12358276
  31. Kiss, 2005, Experimental bullous pemphigoid generated in mice with an antigenic epitope of the human hemidesmosomal protein BP230, J Autoimmun, 24, 1, 10.1016/j.jaut.2004.09.007 · doi:10.1016/j.jaut.2004.09.007
  32. Yoshida, 2006, Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid, J Dermatol Sci, 41, 21, 10.1016/j.jdermsci.2005.11.002 · doi:10.1016/j.jdermsci.2005.11.002
  33. Gammon, 1984, Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1·0 M sodium chloride-separated skin, J Invest Dermatol, 82, 139, 10.1111/1523-1747.ep12259692 · doi:10.1111/1523-1747.ep12259692
  34. Charneux, 2011, Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients, Arch Dermatol, 147, 286, 10.1001/archdermatol.2011.23 · doi:10.1001/archdermatol.2011.23
  35. Roussel, 2011, Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid, Arch Dermatol, 147, 293, 10.1001/archdermatol.2011.21 · doi:10.1001/archdermatol.2011.21
  36. Bernard, 2009, Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study, Arch Dermatol, 145, 537, 10.1001/archdermatol.2009.53 · doi:10.1001/archdermatol.2009.53
  37. Hofmann, 2003, Diagnostic value of an enzyme-linked immunosorbent assay using BP180 recombinant proteins in elderly patients with pruritic skin disorders, Br J Dermatol, 149, 910, 10.1046/j.1365-2133.2003.05603.x · doi:10.1046/j.1365-2133.2003.05603.x
  38. Wieland, 2010, Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects, Arch Dermatol, 146, 21, 10.1001/archdermatol.2009.331 · doi:10.1001/archdermatol.2009.331
  39. Rose, 2009, Histopathology of anti-laminin 5 mucous membrane pemphigoid, J Am Acad Dermatol, 61, 433, 10.1016/j.jaad.2009.02.012 · doi:10.1016/j.jaad.2009.02.012
  40. Kjellman, 2008, A retrospective analysis of patients with bullous pemphigoid treated with methotrexate, Arch Dermatol, 144, 612, 10.1001/archderm.144.5.612 · doi:10.1001/archderm.144.5.612
  41. Schmidt, 2005, Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: a retrospective study of 62 cases, Cutis, 76, 205
  42. Chave, 2004, Chlorambucil as a steroid-sparing agent in bullous pemphigoid, Br J Dermatol, 151, 1107, 10.1111/j.1365-2133.2004.06241.x · doi:10.1111/j.1365-2133.2004.06241.x
  43. Du-Thanh, 2011, Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study, Br J Dermatol, 165, 1337, 10.1111/j.1365-2133.2011.10531.x · doi:10.1111/j.1365-2133.2011.10531.x
  44. Chan, 2002, The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators, Arch Dermatol, 138, 370, 10.1001/archderm.138.3.370 · doi:10.1001/archderm.138.3.370
  45. Thorne, 2004, Mucous membrane pemphigoid and pseudopemphigoid, Ophthalmology, 111, 45, 10.1016/j.ophtha.2003.03.001 · doi:10.1016/j.ophtha.2003.03.001
  46. Ahmed, 1991, Cicatricial pemphigoid, J Am Acad Dermatol, 24, 987, 10.1016/0190-9622(91)70159-Y · doi:10.1016/0190-9622(91)70159-y
  47. Delgado, 1996, A common major histocompatibility complex class II allele HLA-DQB1* 0301 is present in clinical variants of pemphigoid, Proc Natl Acad Sci USA, 93, 8569, 10.1073/pnas.93.16.8569 · doi:10.1073/pnas.93.16.8569
  48. Saw, 2008, Ocular mucous membrane pemphigoid: diagnosis and management strategies, Ocul Surf, 6, 128, 10.1016/S1542-0124(12)70281-1 · doi:10.1016/s1542-0124(12)70281-1
  49. Oyama, 2006, Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity, Br J Dermatol, 154, 90, 10.1111/j.1365-2133.2005.06998.x · doi:10.1111/j.1365-2133.2005.06998.x
  50. Domloge-Hultsch, 1992, Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease, J Clin Invest, 90, 1628, 10.1172/JCI116033 · doi:10.1172/jci116033
  51. Balding, 1996, Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain, J Invest Dermatol, 106, 141, 10.1111/1523-1747.ep12329728 · doi:10.1111/1523-1747.ep12329728
  52. Kirtschig, 1995, Anti-basement membrane autoantibodies in patients with anti-epiligrin cicatricial pemphigoid bind the alpha subunit of laminin 5, J Invest Dermatol, 105, 543, 10.1111/1523-1747.ep12323431 · doi:10.1111/1523-1747.ep12323431
  53. Rashid, 2006, Antigen specificity in subsets of mucous membrane pemphigoid, J Invest Dermatol, 126, 2631, 10.1038/sj.jid.5700465 · doi:10.1038/sj.jid.5700465
  54. Lazarova, 2000, Human anti-laminin 5 autoantibodies induce subepidermal blisters in an experimental human skin graft model, J Invest Dermatol, 114, 178, 10.1046/j.1523-1747.2000.00829.x · doi:10.1046/j.1523-1747.2000.00829.x
  55. Lazarova, 2000, Fab fragments directed against laminin 5 induce subepidermal blisters in neonatal mice, Clin Immunol, 95, 26, 10.1006/clim.2000.4845 · doi:10.1006/clim.2000.4845
  56. Rashid, 2006, Identification of an epitope within human integrin α6 subunit for the binding of autoantibody and its role in basement membrane separation in oral pemphigoid, J Immunol, 176, 1968, 10.4049/jimmunol.176.3.1968 · doi:10.4049/jimmunol.176.3.1968
  57. Chan, 1999, The role of antibody to human β4 integrin in conjunctival basement membrane separation: possible in vitro model for ocular cicatricial pemphigoid, Invest Ophthalmol Vis Sci, 40, 2283
  58. Foster, 2004, Ocular cicatricial pemphigoid review, Curr Opin Allergy Clin Immunol, 4, 435, 10.1097/00130832-200410000-00017 · doi:10.1097/00130832-200410000-00017
  59. Setterfield, 1998, Mucous membrane pemphigoid: a dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease, Br J Dermatol, 138, 602, 10.1046/j.1365-2133.1998.02168.x · doi:10.1046/j.1365-2133.1998.02168.x
  60. Lazarova, 2004, Comparative analysis of methods for detection of anti-laminin 5 autoantibodies in patients with anti-epiligrin cicatricial pemphigoid, J Am Acad Dermatol, 51, 886, 10.1016/j.jaad.2004.06.004 · doi:10.1016/j.jaad.2004.06.004
  61. Kirtschig, 2009, Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita, Cochrane Database Syst Rev, 4
  62. Saw, 2008, Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes, Ophthalmology, 115, 253, 10.1016/j.ophtha.2007.04.027 · doi:10.1016/j.ophtha.2007.04.027
  63. Letko, 2004, A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies, Clin Immunol, 111, 303, 10.1016/j.clim.2003.11.002 · doi:10.1016/j.clim.2003.11.002
  64. Le Roux-Villet, 2011, Rituximab for patients with refractory mucous membrane pemphigoid, Arch Dermatol, 147, 843, 10.1001/archdermatol.2011.54 · doi:10.1001/archdermatol.2011.54
  65. Nanda, 2004, Spectrum of autoimmune bullous diseases in Kuwait, Int J Dermatol, 43, 876, 10.1111/j.1365-4632.2004.02292.x · doi:10.1111/j.1365-4632.2004.02292.x
  66. Jenkins, 1999, Clinical features and management of 87 patients with pemphigoid gestationis, Clin Exp Dermatol, 24, 255, 10.1046/j.1365-2230.1999.00472.x · doi:10.1046/j.1365-2230.1999.00472.x
  67. Intong, 2011, Pemphigoid gestationis: pathogenesis and clinical features, Dermatol Clin, 29, 447, 10.1016/j.det.2011.03.002 · doi:10.1016/j.det.2011.03.002
  68. Morrison, 1988, Herpes gestationis autoantibodies recognize a 180-kD human epidermal antigen, J Clin Invest, 81, 2023, 10.1172/JCI113554 · doi:10.1172/jci113554
  69. Chimanovitch, 1999, IgG1 and IgG3 are the major immunoglobulin subclasses targeting epitopes within the NC16A domain of BP180 in pemphigoid gestationis, J Invest Dermatol, 113, 140, 10.1046/j.1523-1747.1999.00622.x · doi:10.1046/j.1523-1747.1999.00622.x
  70. Powell, 2005, Usefulness of BP180 NC16a enzyme-linked immunosorbent assay in the serodiagnosis of pemphigoid gestationis and in differentiating between pemphigoid gestationis and pruritic urticarial papules and plaques of pregnancy, Arch Dermatol, 141, 705, 10.1001/archderm.141.6.705 · doi:10.1001/archderm.141.6.705
  71. Herrero-Gonzalez, 2006, Immunoadsorption against two distinct epitopes on human type XVII collagen abolishes dermal-epidermal separation induced in vitro by autoantibodies from pemphigoid gestationis patients, Eur J Immunol, 36, 1039, 10.1002/eji.200535349 · doi:10.1002/eji.200535349
  72. Chi, 2009, Pemphigoid gestationis: early onset and blister formation are associated with adverse pregnancy outcomes, Br J Dermatol, 160, 1222, 10.1111/j.1365-2133.2009.09086.x · doi:10.1111/j.1365-2133.2009.09086.x
  73. Wong, 2002, Spectrum of subepidermal immunobullous disorders seen at the National Skin Centre, Singapore: a 2-year review, Br J Dermatol, 147, 476, 10.1046/j.1365-2133.2002.04919.x · doi:10.1046/j.1365-2133.2002.04919.x
  74. Wojnarowska, 1988, Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap, J Am Acad Dermatol, 19, 792, 10.1016/S0190-9622(88)70236-4 · doi:10.1016/s0190-9622(88)70236-4
  75. Zone, 1990, Identification of the cutaneous basement membrane zone antigen and isolation of antibody in linear immunoglobulin A bullous dermatosis, J Clin Invest, 85, 812, 10.1172/JCI114508 · doi:10.1172/jci114508
  76. Zillikens, 1999, Autoantibodies in a subgroup of patients with linear IgA disease react with the NC16A domain of BP1801, J Invest Dermatol, 113, 947, 10.1046/j.1523-1747.1999.00808.x · doi:10.1046/j.1523-1747.1999.00808.x
  77. Zone, 2004, IgA autoimmune disorders: development of a passive transfer mouse model, J Investig Dermatol Symp Proc, 9, 47, 10.1111/j.1087-0024.2004.00840.x · doi:10.1111/j.1087-0024.2004.00840.x
  78. Ng, 2011, Management of linear IgA disease, Dermatol Clin, 29, 629, 10.1016/j.det.2011.06.014 · doi:10.1016/j.det.2011.06.014
  79. Roenigk, 1971, Epidermolysis bullosa acquisita. Report of three cases and review of all published cases, Arch Dermatol, 103, 1, 10.1001/archderm.1971.04000130003001 · doi:10.1001/archderm.1971.04000130003001
  80. Buijsrogge, 2011, The many faces of epidermolysis bullosa acquisita after serration pattern analysis by direct immunofluorescence microscopy, Br J Dermatol, 165, 92, 10.1111/j.1365-2133.2011.10346.x · doi:10.1111/j.1365-2133.2011.10346.x
  81. Chen, 2002, The epidermolysis bullosa acquisita antigen (type VII collagen) is present in human colon and patients with crohn's disease have autoantibodies to type VII collagen, J Invest Dermatol, 118, 1059, 10.1046/j.1523-1747.2002.01772.x · doi:10.1046/j.1523-1747.2002.01772.x
  82. Woodley, 1988, Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen, J Clin Invest, 81, 683, 10.1172/JCI113373 · doi:10.1172/jci113373
  83. Hirose, 2012, Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen, J Autoimmun, 39, 304, 10.1016/j.jaut.2012.04.002 · doi:10.1016/j.jaut.2012.04.002
  84. Vodegel, 2004, U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases, Br J Dermatol, 151, 112, 10.1111/j.1365-2133.2004.06006.x · doi:10.1111/j.1365-2133.2004.06006.x
  85. Saleh, 2011, Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients, J Dermatol Sci, 62, 169, 10.1016/j.jdermsci.2011.03.003 · doi:10.1016/j.jdermsci.2011.03.003
  86. Dainichi, 2010, From anti-p200 pemphigoid to anti-laminin γ1 pemphigoid, J Dermatol, 37, 231, 10.1111/j.1346-8138.2009.00793.x · doi:10.1111/j.1346-8138.2009.00793.x
  87. Groth, 2011, Development of a simple ELISA for the detection of autoantibodies in anti-p200 pemphigoid, Br J Dermatol, 164, 76, 10.1111/j.1365-2133.2010.10056.x · doi:10.1111/j.1365-2133.2010.10056.x
  88. Zillikens, 1999, Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180, J Invest Dermatol, 113, 117, 10.1046/j.1523-1747.1999.00618.x · doi:10.1046/j.1523-1747.1999.00618.x

Cited by

See all 1,015

Metadata

Authors
Schmidt, E., & Zillikens, D.
Venue
The Lancet
Publisher
Elsevier BV
Published
2013-01
Volume
381
Issue
9863
Pages
320-332
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(12)61140-4
OpenAlex
W4211003831
Cited by
1,015
References
62
FWCI
24.11
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pemphigoid diseases. https://app.cochat.ai/papers/10.1016/s0140-6736(12)61140-4
The paper
Schmidt, E., & Zillikens, D. (2013). Pemphigoid diseases. The Lancet. https://doi.org/10.1016/s0140-6736(12)61140-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.